SI-BONE, Inc. (SIBN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 73 | 90 | 106 | 139 | 167 | 201 | 214 | 232 |
| Operating profit | $m | -22 | -18 | ||||||
| Net profit | $m | -44 | -57 | -61 | -43 | -31 | -19 | -15 | -18 |
| EPS reported | $ | -0.44 | -0.34 | ||||||
| Operating cashflow per share | $ | -0.02 | 0.06 | ||||||
| Capex per share | $ | 0.19 | 0.16 | ||||||
| FCF per share | $ | -0.21 | -0.10 | ||||||
| Free cash flow | $m | -9 | -4 | ||||||
| Net debt | $m | -147 | -146 | ||||||
| Book value equity | $m | 178 | 182 | ||||||
| Book value per share | $ | 4.08 | 4.12 | ||||||
| Number of shares | m | 43.51 | 44.22 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.83 | 4.71 | ||||||
| P/S LTM | x | 4.27 | 4.02 | ||||||
| P/FCF LTM | x | -94.40 | -195.57 | ||||||
| EV/EBITDA LTM | x | -74.90 | -163.44 | ||||||
| EV/Sales LTM | x | 4.07 | 3.81 | ||||||
| Earnings Yield LTM | % | -2.20% | -1.75% | ||||||
| FCF Yield | % | -1.06% | -0.51% | ||||||
| Quality | |||||||||
| ROE | % | -10.65% | -8.23% | ||||||
| ROIC | % | -10.42% | -7.88% | ||||||
| Operating margin | % | -11.11% | -8.31% | ||||||
| Gross margin | % | +79.57% | +79.53% | ||||||
| FCF/Sales | % | -4.52% | -2.05% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +20.19% | +27.77% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -8.12 | -0.61 | ||||||
| Net Debt/EBITDA | x | 3.77 | 5.19 | ||||||
| EBIT/Net interest | x | -4.23 | -7.13 | ||||||
| Net debt/market cap | % | +0.13% | +0.85% | ||||||
| Net debt/Equity | x | -0.83 | -0.80 | ||||||
| Gross debt/equity | x | 0.01 | 0.04 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free